Your browser doesn't support javascript.
loading
Concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer.
Artículo en Inglés | IMSEAR | ID: sea-43156
ABSTRACT

OBJECTIVES:

To evaluate the outcomes and adverse effects of concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer MATERIAL AND

METHOD:

All eligible, thirty-four patients with bulky stage IB-IIA cervical cancer were assigned to receive weekly cisplatin 40 mg/m2 for 6 cycles concurrently with radiation followed by extrafascial hysterectomy 6 weeks after completion of radiation.

RESULTS:

Estimated 5-year progression-free and disease-free survival rates of 80% were observed after a median follow-up of 42 months. The overall recurrent rate was 18%. Grade 3 neutropenia and anemia were noted in only 5.9% and 2.9%, respectively. All acute toxicities were transient and were manageable. There were no treatment-related deaths or late toxicities.

CONCLUSION:

For appropriately selected patients with bulky stage IB-IIA cervical cancer, concurrent cisplatin-based chemoradiation followed by adjuvant hysterectomy offers an effective treatment option with acceptable toxicity.
Asunto(s)
Texto completo: Disponible Índice: IMSEAR (Asia Sudoriental) Asunto principal: Anciano / Femenino / Humanos / Carcinoma / Neoplasias del Cuello Uterino / Cisplatino / Resultado del Tratamiento / Terapia Combinada / Adulto / Histerectomía Idioma: Inglés Año: 2005 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: IMSEAR (Asia Sudoriental) Asunto principal: Anciano / Femenino / Humanos / Carcinoma / Neoplasias del Cuello Uterino / Cisplatino / Resultado del Tratamiento / Terapia Combinada / Adulto / Histerectomía Idioma: Inglés Año: 2005 Tipo del documento: Artículo